| Identification | Back Directory | [Name]
CDK4/6/1 Inhibitor | [CAS]
2099128-41-1 | [Synonyms]
crozbaciclib
CDK4/6/1 INHIBITOR
CDK4/6/1 Inhibitor,CDK-4/6/1 Inhibitor
5-fluoro-4-(7-fluor-2-methylspiro[cyclopentane-1,3-[3H]indol]-5-yl)-N-[5-(1-methyl-4-piperidineyl)-2-pyridinyl]-2-pyrimidinamine
5-Fluoro-4-(7'-fluoro-2'-methylspiro[cyclopentane-1,3'-[3H]indol]-5'-yl)-N-[5-(1-methyl-4-piperidinyl)-2-pyridinyl]-2-pyrimidinamine
2-Pyrimidinamine, 5-fluoro-4-(7'-fluoro-2'-methylspiro[cyclopentane-1,3'-[3H]indol]-5'-yl)-N-[5-(1-methyl-4-piperidinyl)-2-pyridinyl]- | [Molecular Formula]
C28H30F2N6 | [MDL Number]
MFCD34469214 | [MOL File]
2099128-41-1.mol | [Molecular Weight]
488.57 |
| Chemical Properties | Back Directory | [Boiling point ]
667.1±65.0 °C(Predicted) | [density ]
1.37±0.1 g/cm3(Predicted) | [form ]
Solid | [pka]
8.73±0.10(Predicted) | [color ]
Light yellow to yellow |
| Hazard Information | Back Directory | [Uses]
5-Fluoro-4-(7''-fluoro-2''-methylspiro[cyclopentane-1,3''-[3H]indol]-5''-yl)-N-[5-(1-methyl-4-piperidinyl)-2-pyridinyl]-2-pyrimidinamine is a novel CDK4/6 inhibitor which is designed to overcome blood brain barrier in gliobastoma therapy. | [in vivo]
Crozbaciclib (3.125-50 mg/kg; ) has tumor growth inhibition values ranging from 62% to 99% in an orthotopic xenograft mouse model of glioblastoma multiforme. And Crozbaciclib results insignificant body weight loss. Crozbaciclib increases life span based on the median survival time of vehicle-treated animals in mice is significant at 162%, at a dose of 50 mg/kg[1]. |
|
| Company Name: |
BOC Sciences
|
| Tel: |
1-631-485-4226; 16314854226 |
| Website: |
https://www.bocsci.com |
|